JP2019514899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514899A5 JP2019514899A5 JP2018555870A JP2018555870A JP2019514899A5 JP 2019514899 A5 JP2019514899 A5 JP 2019514899A5 JP 2018555870 A JP2018555870 A JP 2018555870A JP 2018555870 A JP2018555870 A JP 2018555870A JP 2019514899 A5 JP2019514899 A5 JP 2019514899A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- compound according
- compound
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 99
- 229910052739 hydrogen Inorganic materials 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 56
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 37
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 6
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims description 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010018404 Glucagonoma Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000015557 immune complex mediated vasculitis Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000000008 pancreatic gastrinoma Diseases 0.000 claims description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- -1 amide compound Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329708P | 2016-04-29 | 2016-04-29 | |
| US62/329,708 | 2016-04-29 | ||
| PCT/US2017/030185 WO2017190048A1 (en) | 2016-04-29 | 2017-04-28 | Covalent btk inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019514899A JP2019514899A (ja) | 2019-06-06 |
| JP2019514899A5 true JP2019514899A5 (enExample) | 2020-06-11 |
Family
ID=60161148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555870A Withdrawn JP2019514899A (ja) | 2016-04-29 | 2017-04-28 | 共有結合型ｂｔｋ阻害剤及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200339562A1 (enExample) |
| EP (1) | EP3448433A4 (enExample) |
| JP (1) | JP2019514899A (enExample) |
| CN (1) | CN109562181A (enExample) |
| AU (1) | AU2017258649A1 (enExample) |
| CA (1) | CA3021558A1 (enExample) |
| MA (1) | MA44789A (enExample) |
| WO (1) | WO2017190048A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2024215824A1 (en) * | 2023-04-14 | 2024-10-17 | Kuleon Llc | Serotonin receptor modulators and methods of making and using the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215603A1 (en) * | 2004-03-08 | 2005-09-29 | Irini Akritopoulou-Zanze | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
-
2017
- 2017-04-28 CN CN201780040768.3A patent/CN109562181A/zh active Pending
- 2017-04-28 AU AU2017258649A patent/AU2017258649A1/en not_active Abandoned
- 2017-04-28 WO PCT/US2017/030185 patent/WO2017190048A1/en not_active Ceased
- 2017-04-28 MA MA044789A patent/MA44789A/fr unknown
- 2017-04-28 JP JP2018555870A patent/JP2019514899A/ja not_active Withdrawn
- 2017-04-28 CA CA3021558A patent/CA3021558A1/en not_active Abandoned
- 2017-04-28 US US16/097,093 patent/US20200339562A1/en not_active Abandoned
- 2017-04-28 EP EP17790572.6A patent/EP3448433A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535610A5 (enExample) | ||
| JP2015504067A5 (enExample) | ||
| RU2016110755A (ru) | Соединение, ингибирующее активности киназ ВТК и/или JAK3 | |
| JP2008195730A5 (enExample) | ||
| JP2013531031A5 (enExample) | ||
| JP2012144574A5 (enExample) | ||
| JP2013540713A5 (enExample) | ||
| JP2008503473A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2013509429A5 (enExample) | ||
| RU2015107552A (ru) | Бивалентные ингибиторы ингибиторов белков апоптоза и терапевтические способы их применения | |
| JP2015535277A5 (enExample) | ||
| JP2017530130A5 (enExample) | ||
| CN111836807A (zh) | 氧杂螺环类化合物及其制备方法和用途 | |
| RU2016134749A (ru) | Гетероциклическое сульфонамидное производное и лекарственное средство, содержащее такое производное | |
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| MX376269B (es) | Composición que comprende nanopartículas, preparación y su uso en la preparación de un fármaco para el tratamiento del cáncer. | |
| FI3065763T4 (fi) | Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| MX2016015435A (es) | Combinacion farmaceutica que comprende un inhibidor de quinasa de tirosina del receptor clase iii y la molecula de fusion inhibidora de deacetilasa de histona alquilante edo-s101 y su uso en el tratamiento de cancer. | |
| JP2013136567A5 (ja) | 有機金属錯体 | |
| WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
| JP2015519347A5 (enExample) | ||
| JP2016513124A5 (enExample) | ||
| EP4431155A3 (en) | Pharmaceutical composition, preparation and uses thereof |